{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T23:05:55Z","timestamp":1782428755325,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ghir.2017.05.006","type":"journal-article","created":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T08:17:28Z","timestamp":1495613848000},"page":"8-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone"],"prefix":"10.1016","volume":"35","author":[{"given":"Peter","family":"Thygesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Sune","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes Josef","family":"Fels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"N\u00f8rskov-Lauritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rischel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Langeland","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ghir.2017.05.006_bb0005","doi-asserted-by":"crossref","first-page":"e16223","DOI":"10.1371\/journal.pone.0016223","article-title":"Non-compliance with growth hormone treatment in children is common and impairs linear growth","volume":"6","author":"Cutfield","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ghir.2017.05.006_bb0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4158\/EP13194.OR","article-title":"Adherence to growth hormone therapy: results of a multicenter study","volume":"20","author":"Adyin","year":"2014","journal-title":"Endocr. Pract."},{"issue":"2","key":"10.1016\/j.ghir.2017.05.006_bb0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4158\/EP.14.2.143","article-title":"Compliance and persistence in pediatric and adult patients receiving growth hormone therapy","volume":"14","author":"Rosenfeld","year":"2008","journal-title":"Endocr. Pract."},{"issue":"Suppl. 4","key":"10.1016\/j.ghir.2017.05.006_bb0020","first-page":"545","article-title":"Adherence remains a challenge for patients receiving growth hormone therapy","volume":"6","author":"Norgren","year":"2009","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.ghir.2017.05.006_bb0025","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/cen.12240","article-title":"Developing long-acting growth hormone formulations","volume":"79","author":"Cawley","year":"2013","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2017.05.006_bb0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ghir.2015.07.004","volume":"25","author":"H\u00f8ybye","year":"2015","journal-title":"Growth Hormon. IGF Res."},{"issue":"3","key":"10.1016\/j.ghir.2017.05.006_bb0035","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0022-3565(24)38301-6","article-title":"A pharmacokinetic\/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor 1 in monkeys","volume":"289","author":"Sun","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ghir.2017.05.006_bb0040","series-title":"PCDCON: Manual of Deconvolution for Pharmacokinetic Analysis","author":"Gillespie","year":"1999"},{"key":"10.1016\/j.ghir.2017.05.006_bb0045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/jps.2600690314","article-title":"Model-independent method for analyzing input in linear pharmacokinetic systems having polyexponential impulse response I: theoretical analysis","volume":"69","author":"Veng-Pedersen","year":"1980","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ghir.2017.05.006_bb0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF01065657","article-title":"A polyexponential deconvolution method. Evaluation of the gastrointestinal bioavailability and mean in vivo dissolution time of some ibuprofen dosage forms","volume":"13","author":"Gillespie","year":"1985","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ghir.2017.05.006_bb0055","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/1087057106297566","article-title":"A luminescent oxygen channeling immunoassay for the determination of insulin in human plasma","volume":"12","author":"Poulsen","year":"2007","journal-title":"J. Biomol. Screen."},{"issue":"1","key":"10.1016\/j.ghir.2017.05.006_bb0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0003-9861(86)90216-X","article-title":"The primary structure of monkey pituitary growth hormone","volume":"245","author":"Li","year":"1986","journal-title":"Arch. Biochem. Biophys."},{"issue":"8","key":"10.1016\/j.ghir.2017.05.006_bb0065","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1210\/jc.2006-0514","article-title":"Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency","volume":"91","author":"Bidlingmaier","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.ghir.2017.05.006_bb0070","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/jc.2011-2234","article-title":"Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD)","volume":"97","author":"P\u00e9ter","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ghir.2017.05.006_bb0075","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11102-012-0422-8","article-title":"12-month effects of once-weekly sustained-release growth hormone treatment in adults with GH deficiency","volume":"16","author":"Biller","year":"2013","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.ghir.2017.05.006_bb0080","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1210\/jc.2013-1437","article-title":"A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults","volume":"98","author":"Yuen","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.05.006_bb0085","article-title":"A phase 2, multiple-dose, open-label, parallel-group, active controlled, safety, tolerability, pharmacokinetic and Pharmacodynamic study of ACP-001 in adult patients with growth hormone deficiency (AGHD)","volume":"33","author":"H\u00f8ybye","year":"2012","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ghir.2017.05.006_bb0090","first-page":"OC10.5","article-title":"Once-weekly, CTP-modified hGH (MOD-4023) is effective in growth hormone deficient adults: a phase II, dose and frequency finding study","volume":"29","author":"Popovic","year":"2012","journal-title":"Endocr. Abstr."},{"issue":"10","key":"10.1016\/j.ghir.2017.05.006_bb0095","doi-asserted-by":"crossref","first-page":"E1819","DOI":"10.1210\/jc.2014-1702","article-title":"A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile","volume":"99","author":"Rasmussen","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ghir.2017.05.006_bb0100","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1210\/jc.2015-1991","article-title":"Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency","volume":"101","author":"Rasmussen","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2017.05.006_bb0115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0014-2999(02)02644-4","article-title":"Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys","volume":"456","author":"Osborn","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ghir.2017.05.006_bb0120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ghir.2016.08.001","article-title":"Safety and PK\/PD correlation of TV-1106, a recombinant fused human albumin-growth hormone, following repeat dose administration to monkeys","volume":"30-31","author":"Ashkenazi","year":"2016","journal-title":"Growth Hormon. IGF Res."},{"issue":"10","key":"10.1016\/j.ghir.2017.05.006_bb0125","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1021\/acs.molpharmaceut.5b00550","article-title":"Pharmacokinetics, pharmacodynamics, and efficacy of a novel long-acting human growth hormone: fc fusion protein","volume":"12","author":"Kim","year":"2015","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.ghir.2017.05.006_bb0130","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/jps.23229","article-title":"A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life","volume":"101","author":"Cleland","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ghir.2017.05.006_bb0135","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/acs.molpharmaceut.5b00868","article-title":"In vitro and in vivo characterization of MOD-4023, a long-acting carboxy-terminal peptide (CTP)-modified human growth hormone","volume":"13","author":"Hershkovitz","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ghir.2017.05.006_bb0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0773.1988.tb00924.x","article-title":"Pharmacokinetics of biosynthetic and pituitary human growth hormone in rats","volume":"63","author":"J\u00f8rgensen","year":"1988","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.ghir.2017.05.006_bb0145","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/eje.0.1350309","article-title":"Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcuteneous administration","volume":"135","author":"Laursen","year":"1996","journal-title":"Eur. J. Endocrinol."}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637417300394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637417300394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:49:58Z","timestamp":1761086998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637417300394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":27,"alternative-id":["S1096637417300394"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2017.05.006","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2017.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}